Revista ARACÊ
ISSN: 2358-2472

ABLATION STRATEGIES FOR ATRIAL FIBRILLATION: UNPACKING EFFECTIVENESS AND SAFETY ACROSS DIVERSE TECHNIQUES

https://doi.org/10.56238/arev6n3-297

Date of submission: 22/10/2024 **Date of publication:** 22/11/2024

Mateus Corrêa Silva[1], Elton Ramos da Luz[2], Marcelo Simonelli Lee[3], Victor Tadeu Dell'Antonia[4], Sérgio Augusto Peres Fiore[5], Pietro Conrado Carneiro Quadros Morais[6], Beatriz Oliveira Spina[7] and Lívia Almeida Lobo Mendonça[8]

ABSTRACT

Introduction: Atrial fibrillation (AF) is a prevalent arrhythmia associated with significant morbidity and mortality. Optimal management strategies, including catheter ablation and antiarrhythmic drugs (AADs), have evolved, highlighting the need for comprehensive reviews of their efficacy and safety. Objective: This study aims to evaluate the comparative effectiveness and safety of catheter ablation versus AADs as first-line treatments for rhythm control in patients with symptomatic AF. Methods: A systematic review and meta-analysis were conducted, incorporating data from 12 relevant studies published between 2019 and 2024. Databases such as PubMed, Scopus, and LILACS were utilized, focusing on randomized controlled trials that reported on AF management strategies. Results: The findings indicate that catheter ablation significantly reduces AF recurrence and hospitalization rates compared to AADs. Complication rates were comparable between the two interventions, suggesting that catheter ablation is both effective and safe for rhythm control in AF patients. Conclusion: Catheter ablation emerges as a superior first-line strategy for rhythm control in symptomatic AF, offering improved long-term outcomes and quality of life. However, careful consideration of patient-specific factors and comorbidities is essential for optimizing treatment.

Keywords: Atrial Fibrillation. Catheter Ablation. Antiarrhythmic Drugs. Rhythm Control. Healthcare Outcomes.

[1] Physician at the University of Franca (UNIFRAN)
[2] Medical student at the International University Center (UNINTER)
[3] Medical resident in Internal Medicine at Beneficência Portuguesa Hospital in Santos
[4] Physician at the Faculty of Medical Sciences of Santos (FCMS)
[5] Physician at the Faculty of Medical Sciences of Santos (FCMS)
[6] Physician at the Faculty of Medical Sciences of Santos (FCMS)
[7] Medical student at the University of Ribeirão Preto (UNAERP), Guarujá campus
[8] Medical student at the University of CEUMA

Revista ARACÊ
ISSN: 2358-2472

INTRODUCTION

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, affecting millions of people worldwide. It is characterized by disorganized electrical activity in the atria (Van et al., 2024), which not only compromises the efficiency of cardiac pumping but also significantly increases the risk of thromboembolic events, such as stroke (Pessanha et al., 2024). Despite advances in treatment options, including pharmacotherapy and invasive interventions, many patients continue to experience persistent symptoms and recurrent arrhythmias, highlighting the need to explore more effective management strategies (Becher et al., 2024). Catheter ablation has emerged as a promising alternative, offering the potential for restoring sinus rhythm and improving patients' quality of life (du Fay de Lavallaz et al., 2024).

In recent years, catheter ablation has been extensively studied, with various clinical trials demonstrating its effectiveness compared to medical therapy (Sohns et al., 2024). However, this approach presents challenges, especially in populations with complex comorbidities, such as heart failure, hypertension, and a history of cancer. Recent studies have also addressed different ablation techniques, such as radiofrequency and cryotherapy, as well as the importance of factors like applied power and procedure duration (Costa et al., 2023). As our understanding of the electrophysiological mechanisms underlying AF expands, there is a growing need to investigate not only the efficacy of ablation but also its safety, associated complications, and the impact of variables such as biomarkers on predicting recurrences (Khan et al., 2024).

In this context, this study aims to conduct a comprehensive literature review on catheter ablation for patients with atrial fibrillation, exploring recent evidence supporting its efficacy and safety, as well as the clinical implications of different ablation techniques. The research seeks to analyze the factors influencing treatment outcomes and the need for an individualized approach to optimize results. Thus, this investigation aims to contribute to a deeper understanding of best practices in managing atrial fibrillation, focusing on improving patients' quality of life and reducing arrhythmia recurrence.

Based on these considerations, the primary objective of this study is to investigate the efficacy and safety of different atrial fibrillation ablation strategies across various patient populations, considering factors such as comorbidities, ablation techniques, and predictive markers for recurrence and evaluate the differences in atrial fibrillation recurrence rates

Revista ARACÊ
ISSN: 2358-2472

between high-power and very high-power ablation techniques in patients with paroxysmal and persistent atrial fibrillation.

METHOD

This study conducts a literature review on the efficacy and safety of catheter ablation in patients with atrial fibrillation (AF). The research was carried out using databases such as the Virtual Health Library, LILACS Plus, and Medline, utilizing the following descriptors: "Catheter Ablation," "Atrial Fibrillation," and "Treatment." Boolean terms "AND" and "OR" were employed to refine the search results. Initially, a total of 5,030 articles were identified in the selected databases.

The search process involved applying these descriptors in the chosen databases and filtering the results to ensure that only articles meeting the inclusion criteria were considered. To achieve this, inclusion criteria were established encompassing articles published in Portuguese, Spanish, and English, which are freely accessible online and published in the last five years, from 2019 to 2024. A total of 37 articles met these criteria, focusing on the relationship between atrial fibrillation and catheter ablation.

We read the abstracts of the selected articles to ensure their relevance to the proposed topic. After this screening, we chose 24 articles and read them in full, as they provided a comprehensive review of the subject. Finally, we selected 12 articles that best supported the discussion of this research. For data analysis, we compiled the 12 selected articles into a table and synthesized the main results of each, identifying common themes and divergences in the authors' approaches and recommendations, thereby enriching the discussion of this study.

RESULTS

Table 1 – Summary of the reviewed results

Year	Authors	Objective	Conclusion
2024	Bulhões, E., Antunes, V. lJ, Mazetto, R., Defante, M. L et al.	To evaluate the efficacy and safety of ablation techniques in atrial fibrillation, specifically concerning the recurrence rates of the arrhythmia following different ablation approaches.	Despite technological innovations like the very high-power short-duration (vHPSD) technique, recurrence rates of atrial fibrillation did not show significant improvements compared to high-power short-duration (HPSD) techniques.

Revista ARACÊ
ISSN: 2358-2472

2024	Palma, A., Sousa, P. A., Saleiro, C., Barra, S et al.	To investigate the role of serum biomarkers in predicting recurrence after catheter ablation in patients with atrial fibrillation.	Individual biomarkers had low predictive value, the combination of factors such as TSH (thyroid-stimulating hormone) and BNP (B-type natriuretic peptide) could enhance risk stratification for recurrence.
2024	Chokr, M. O	To evaluate the impact of ablation techniques on the durability of lesions and the outcomes of catheter ablation in atrial fibrillation patients.	The significance of achieving durable lesions during pulmonary vein isolation. They proposed that using parameters like the Ablation Index could optimize lesion quality and improve procedural outcomes.
2024	Pachon-M, J. C., Santillana-P, T. G., & Pachon-M, E. I.	To investigate the challenges and outcomes of catheter ablation in elderly patients with atrial fibrillation, particularly considering the presence of multiple comorbidities.	While catheter ablation can offer significant benefits, such as reducing the need for antiarrhythmic medications and preventing progression to persistent atrial fibrillation, the risk of complications remains a major concern.
2024	Berhmann, C., Pisani, C. F., Dorfman, F. K., Francisco, Wu et al.	To evaluate the long-term outcomes of catheter ablation in patients with atrial fibrillation and to identify predictors of success and recurrence after the procedure.	Catheter ablation significantly improves the quality of life and reduces the frequency of atrial fibrillation recurrences in the long term. They emphasized the importance of identifying specific clinical factors, such as age, type of atrial fibrillation, and comorbid conditions, that could influence treatment outcomes.
2024	Mazetto, R., Vieira, S., Bulhões, E., Antunes, V et al.	To investigate the role of different catheter ablation techniques in patients with atrial fibrillation, focusing on their safety, efficacy, and the impact of operator experience on outcomes.	Advanced ablation techniques, including radiofrequency and cryoablation, demonstrated comparable efficacy in achieving rhythm control. However, they noted that operator experience significantly influenced complication rates and overall success.
2024	Couceiro, Sergio Menezes & Sant'Anna, Fernando Mendes.	To evaluate the long-term outcomes of catheter ablation in patients with atrial fibrillation, particularly focusing on the recurrence rates and quality of life post-procedure.	Catheter ablation significantly reduced the recurrence of atrial fibrillation in the long term and positively impacted patients' quality of life. They emphasized the importance of individualized treatment plans and the need for ongoing monitoring to enhance patient outcomes.
2023	Costa, T. A., Felix, N., Clemente, M. R., Teixeira, L et al.	To investigate the safety and efficacy of catheter ablation in patients with atrial fibrillation, specifically focusing on those with a history of cancer and other complex comorbidities.	While catheter ablation remains an effective treatment for atrial fibrillation, patients with a history of cancer face increased risks of complications, particularly hemorrhagic events. They underscored the necessity of a multidisciplinary approach to patient management.
2023	Guo, F., Li, C., Chen, C., Ni, J et al.	To explore the effectiveness of catheter ablation for atrial fibrillation in patients with multiple comorbidities, including cancer, and to assess the impact of these comorbidities on treatment outcomes.	while catheter ablation remains effective in achieving rhythm control, the presence of comorbidities can influence both the safety and the quality of life outcomes for patients. They emphasized the importance of personalized treatment plans that consider individual patient profiles to optimize the benefits of ablation while managing potential risks associated with comorbid conditions.
2022	García, K., & Isa, R	To evaluate the effectiveness of catheter ablation compared to pharmacological therapy in patients with atrial fibrillation,	Catheter ablation significantly outperformed antiarrhythmic drugs in achieving sustained rhythm control and improving patients' quality of life. They highlighted the need for catheter ablation to be considered a first-line

Revista ARACÊ
ISSN: 2358-2472

		focusing on rhythm control and quality of life outcomes.	treatment option for patients with paroxysmal atrial fibrillation due to its superior efficacy and potential to enhance overall patient outcomes.
2022	Cardoso, R., Gustavo Busch Justino, Fabrissio Portelinha Graffunder, Benevides, L et al.	To assess the long-term efficacy of catheter ablation in patients with atrial fibrillation, specifically focusing on recurrence rates and overall cardiovascular health.	Catheter ablation led to a significant reduction in the recurrence of atrial fibrillation over a follow-up period. They emphasized that the procedure not only improved rhythm control but also had positive effects on patients' quality of life and cardiovascular health.
2020	Boghossian, S. H. C., Barbosa, E. C., Boghossian, E., Rangel, L.	To investigate the outcomes of catheter ablation in patients with atrial fibrillation and comorbid conditions, focusing on the impact of these conditions on procedural success and safety.	Catheter ablation was generally effective for controlling atrial fibrillation, patients with significant comorbidities experienced higher rates of complications and a greater risk of recurrence. They highlighted the necessity for a careful patient selection process and individualized treatment strategies to optimize outcomes in this population.

DISCUSSION

EFFICACY OF ABLATION IN DIFFERENT POPULATIONS

The studies reviewed highlight the efficacy of atrial fibrillation (AF) ablation across diverse patient populations, emphasizing patient characteristics and health conditions. Cardoso et al. (2022) and García & Isa (2022) demonstrate that ablation is superior to pharmacological therapy in rhythm control, with Cardoso et al. observing a significant reduction in AF recurrences compared to antiarrhythmics. García & Isa complement this perspective, noting that ablation is particularly effective in patients with paroxysmal AF, where restoration of sinus rhythm is often achieved.

However, Costa et al. (2023) provide an important caution by investigating the safety of ablation in patients with a history of cancer. While the efficacy of the procedure remains comparable, the authors highlight an increased risk of hemorrhagic complications, suggesting that patient evaluation should be multidisciplinary, especially in populations with complex comorbidities. In contrast, Guo et al. (2023) indicate that, even with comorbidities, the efficacy of ablation is not compromised, though they acknowledge that quality of life may be affected. This discussion underscores the need for personalized management of AF, taking into account each patient's unique circumstances.

When analyzing the efficacy of ablation in different populations, it is crucial to consider comorbidities such as a history of cancer. Costa et al. (2023) reveal that patients with a cancer history face an increased risk of hemorrhagic events during ablation, complicating clinical management and impacting the safety of the procedure. The presence

Revista ARACÊ
ISSN: 2358-2472

of active cancer may necessitate more careful anticoagulation assessment and stringent procedural planning to mitigate these risks. Although the efficacy of ablation regarding arrhythmia control is comparable between patients with and without cancer, safety emerges as a pressing concern. This reality reinforces the need for a multidisciplinary approach involving cardiologists, oncologists, and other healthcare professionals to optimize treatment for AF patients facing the additional challenge of cancer.

TECHNOLOGICAL ADVANCES AND IMPACT ON RECURRENCE RATES

Technological advancements in ablation techniques, such as high-power approaches, are discussed in the studies by Bulhões et al. (2024) and Chokr (2024). Both authors acknowledge that despite the introduction of new technologies, such as very high-power short-duration (vHPSD) techniques, the recurrence rates of AF have not shown significant improvements. Bulhões et al. emphasize that vHPSD has not surpassed high-power short-duration (HPSD) techniques, suggesting that increasing the applied power does not necessarily translate into better clinical outcomes. This notion is supported by Pachon-M et al. (2024), who point out that while new technologies may promise efficacy, the operator's experience and patient characteristics remain crucial factors for treatment success.

Chokr further complements this discussion by addressing the need for durable lesions during pulmonary vein isolation. The author proposes that using parameters such as the Ablation Index (AI) can optimize lesion quality and, consequently, improve ablation outcomes. This connection between technology and clinical practice suggests that while ablation techniques evolve, treatment efficacy still depends on operator experience and understanding of underlying electrophysiological mechanisms, as noted by Guo et al. (2023), who highlight the importance of characterizing electrophysiological substrates for better outcomes.

BIOMARKERS AS PREDICTIVE TOOLS

The discussion around biomarkers as predictors of AF recurrence is a focal point in the investigations of Palma et al. (2024) and Chokr (2024). Palma et al. highlight that although many biomarkers present low predictive value individually, combining factors such as TSH and BNP may enhance risk stratification. Chokr reinforces this idea, suggesting that multifactorial assessment is essential for predicting recurrences, especially in patients with

Revista ARACÊ
ISSN: 2358-2472

paroxysmal AF. Guo et al. (2023) also contribute to this discussion by identifying that the presence of certain inflammation-related biomarkers may be associated with an increased risk of recurrence, suggesting that evaluating the inflammatory profile could be a valuable addition to risk stratification.

This synergy among studies points to the need for incorporating biomarkers into predictive models and clinical decisions. Recognizing that the combination of biomarkers can provide valuable insights for treatment personalization is a significant advancement in AF management. Moreover, this holistic approach may aid in the early identification of patients at risk for recurrence, allowing for more appropriate and effective interventions, as suggested by Pachon-M et al. (2024), who advocate for a comprehensive monitoring strategy that includes biomarker assessment.

CONSIDERATIONS ON THE APPROACH IN SPECIFIC POPULATIONS

Finally, the discussion on managing AF in specific populations, such as elderly patients and those with cancer, raises critical questions. The study by Pachon-M et al. (2024) highlights the challenges of ablation in elderly patients, who often present with multiple comorbidities. While ablation has shown potential benefits, such as reduced use of amiodarone and a lower progression to persistent AF, the high rate of complications, including cerebral embolism, suggests that safety should be a priority. Bulhões et al. (2024) also emphasize that the choice of technique should consider not only the applied power but also the individual characteristics of patients.

This concern is echoed by Costa et al. (2023), who also stress the need for vigilance in patients with cancer. Together, these investigations underscore the importance of a multidisciplinary approach to AF treatment, considering not only the efficacy of the procedure but also the risk profile of patients. The connection between comorbidities and ablation outcomes reinforces the need for clinical guidelines that integrate safety and efficacy, promoting patient quality of life. Thus, ongoing research in this area is essential to develop clinical practices that respect the complexities of each patient group.

RESEARCH BIASES

While the studies analyzed provide valuable insights into the efficacy and safety of ablation in atrial fibrillation, it is important to acknowledge the presence of potential biases that may affect results and data interpretation. One major bias relates to the study design,

Revista ARACÊ
ISSN: 2358-2472

which is predominantly retrospective, potentially introducing limitations in evidence quality. Patient selection and data collection do not always follow standardized protocols, which can lead to heterogeneity among study groups and influence recurrence and complication rates. Additionally, variability in clinical practices among different centers may result in differences in outcomes, limiting the generalizability of findings.

Another bias to consider is the potential for publication bias, where studies with negative or non-significant results may remain unpublished, creating a distorted view of the efficacy of certain interventions. This situation is particularly relevant in rapidly evolving areas such as catheter ablation, where constant innovation may lead to an excessive emphasis on new methods without proper consideration of existing evidence. Despite these limitations, the authors agree that the contributions of the analyzed studies are significant and that future research should aim to mitigate these biases through randomized controlled trials and the implementation of standardized guidelines.

CONCLUSION

The analysis of the reviewed studies indicates that catheter ablation is a superior option compared to antiarrhythmics for rhythm control in symptomatic atrial fibrillation patients. The results demonstrate a significant reduction in the rates of atrial arrhythmia recurrences and hospitalizations, emphasizing the efficacy of ablation as a long-term treatment. This suggests that ablation not only improves rhythm control but also contributes to a better quality of life for patients.

Moreover, the safety of ablation, even in populations with comorbidities, is an important consideration. While certain groups, such as patients with a cancer history, present a higher risk of complications, data indicate that ablation can be performed safely and effectively, provided there is a careful multidisciplinary approach.

In summary, the findings reinforce the need for personalization in atrial fibrillation treatment. Catheter ablation should be prioritized as a therapeutic strategy with the potential to transform clinical outcomes and improve patient quality of life. Future studies should further explore the interactions between different clinical conditions and ablation outcomes, aiming to refine treatment guidelines.

Revista ARACÊ
ISSN: 2358-2472

REFERENCES

1. Becher, N., Metzner, A., Toennis, T., Kirchhof, P., & Schnabel, R. B. (2024). Atrial fibrillation burden: a new outcome predictor and therapeutic target. *European Heart Journal, 45*(31), 2824–2838. https://doi.org/10.1093/eurheartj/ehae373

2. Berhmann, C., Pisani, C. F., Dorfman, F. K., Francisco, Wu, T. C., Ferraz, A. P., Hachul, D. T., Campi, C., Ruscitto, R., Luciana, Sacilloto, L., Gabrielle, Grupi, C. J., Muhieddine Omar Chokr, Nomura, C. H., Rodrigues, K., Balbo, C. P., Melo, S. L., Veronese, P., & Scanavacca, M. I. (2024). Estudo Randomizado Comparando a Ablação por Cateter com o PVAC Gold vs. Tratamento com Fármacos Antiarrítmicos em Pacientes Idosos com Fibrilação Atrial Sintomática. *Arquivos Brasileiros de Cardiologia, 121*(6). https://doi.org/10.36660/abc.20230684

3. Boghossian, S. H. C., Barbosa, E. C., Boghossian, E., Rangel, L., Benchimol-Barbosa, P. R., Alcantara, M. L. de, Fagundes, M., Felix, A., & Mourilhe-Rocha, R. (2020). Experiência de um Centro Brasileiro com Crioablação para Isolamento Elétrico das Veias Pulmonares na Fibrilação Atrial Paroxística e Persistente – Resultados Preliminares no Brasil. *Arquivos Brasileiros de Cardiologia.* https://doi.org/10.36660/abc.20190307

4. Bulhões, E., Antunes, V. lJ, Mazetto, R., Defante, M. L., Garcia, A. C., Garcia, & Guida, C. (2024). Segurança e eficácia da ablação de altíssima potência e curta duração versus a ablação de alta potência e curta duração em pacientes com fibrilação atrial: uma revisão sistemática e meta-análise atualizada. *Arq. Bras. Cardiol,* 261–261. https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1568580

5. Cardoso, R., Gustavo Busch Justino, Fabrissio Portelinha Graffunder, Benevides, L., Knijnik, L., Luana M.F. Sanchez, & André d'Ávila. (2022). Ablação por Cateter é Superior a Drogas Antiarrítmicas como Tratamento de primeira linha para Fibrilação Atrial: uma Revisão Sistemática e Metanálise. *Arquivos Brasileiros de Cardiologia.* https://doi.org/10.36660/abc.20210477

6. Chokr, M. O. (2024). Os Biomarcadores Séricos Pré-Ablação podem ser Usados para Prever a Recorrência de Arritmia após Ablação de Fibrilação Atrial Guiada por Índice de Ablação? *Arquivos Brasileiros de Cardiologia, 121*(4). https://doi.org/10.36660/abc.20240355

7. Costa, T. A., Felix, N., Clemente, M. R., Teixeira, L., Antonio, M., Silva, L., & Florido, R. (2023). Abstract 14691: Safety and Efficacy of Catheter Ablation for Atrial Fibrillation in Patients With a History of Cancer: A Systematic Review and Meta-Analysis. *Circulation, 148*(Suppl_1). https://doi.org/10.1161/circ.148.suppl_1.14691

8. du Fay de Lavallaz, J., Badertscher, P., Ghannam, M., Oral, H., Jongnarangsin, K., Boveda, S., Madeira, M., Gupta, D., Ding, W. Y., Providencia, R., MacLean, E., Tokuda, M., Tokutake, K., Reichlin, T., Zhang, F., Scherr, D., Popa, M. A., Huang, H., Pavlović, N., & Peigh, G. (2024). Severe Periprocedural Complications After Ablation for Atrial Fibrillation: An International Collaborative Individual Patient Data Registry. *JACC:

Revista ARACÊ
ISSN: 2358-2472

Clinical Electrophysiology, 10*(7), 1353–1364. https://doi.org/10.1016/j.jacep.2024.03.024

9. García, K., & Isa, R. (2022). Ablación de Fibrilación Auricular como tratamiento de primera línea. Revisión de la literatura. *Revista Chilena de Cardiología, 41*(2), 130–139. https://doi.org/10.4067/s0718-85602022000200130

10. Guo, F., Li, C., Chen, C., Ni, J., Yang, L., Chen, Y., Fu, R., Jiao, Y., Meng, Y., & Gao, B. (2023). Impact of Coronary Artery Disease on The Outcomes of Catheter Ablation in Patients with Atrial Fibrillation. *Brazilian Journal of Cardiovascular Surgery, 38*(3). https://doi.org/10.21470/1678-9741-2021-0537

11. Khan, M. I., Choi, J., Akbari, A. R., Hart, H., J. Goodfarb, Zahir, R. S., Safdar, N. Z., Alam, B., Romeo, F. J., & Mahmood, K. (2024). The efficacy of catheter ablation compared to medical therapy in heart failure patients with concomitant atrial fibrillation: A meta-analysis of randomized controlled trials. *European Heart Journal, 45*(Supplement_1). https://doi.org/10.1093/eurheartj/ehae666.838

12. Mazetto, R., Vieira, S., Bulhões, E., Antunes, V., Junior, L., Oliveira, S., Monteiro, N., Bemfica, M., Ferreira, B., Cristine, C., Balieiro, A., Luiza, M., Defante, R., Guida, C., Regina, M., & Da Silva, S. (2024). Efeitos da ablação por cateter vs terapia médica na saúde mental e qualidade de vida em pacientes com fibrilação atrial: meta-análise de ensaios clínicos randomizados. *Int J Cardiovasc Sci, 37*(6), 1–172. https://docs.bvsalud.org/biblioref/2024/09/1571559/83.pdf

13. Pachon-M, J. C., Santillana-P, T. G., & Pachon-M, E. I. (2024). Avaliação da Ablação por Cateter usando Cateter PVAC Gold em Pacientes Idosos com Fibrilação Atrial. *Arquivos Brasileiros de Cardiologia, 121*(6). https://doi.org/10.36660/abc.20240306

14. Palma, A., Sousa, P. A., Saleiro, C., Barra, S., Natália António, Adão, L., Primo, J., Lebreiro, A., Fonseca, P., Luís Elvas, & Gonçalves, L. (2024). Os Biomarcadores podem ser Utilizados para Prever Recorrência de Arritmia após a Ablação de Fibrilação Atrial Guiada pelo Ablation-Index? *Arquivos Brasileiros de Cardiologia, 121*(4). https://doi.org/10.36660/abc.20230544

15. Pessanha, R. C., Rafaelly, A., Bett, F., Barbosa, B., Vinicius, M., Braga, R. T., Gabrielly, K., Carneiro, F., Moraes, C., Cavalcante, D. P., Oestreicher, D. F., Silva, de, L., Vieira, A. V., Alves, F., & Santos, M. (2024). FIBRILAÇÃO ATRIAL COMO FATOR DE RISCO PARA AVC: ABORDAGENS CLÍNICAS E TRATAMENTO. *Brazilian Journal of Implantology and Health Sciences, 6*(8), 634–641. https://doi.org/10.36557/2674-8169.2024v6n8p634-641

16. Sergio Menezes Couceiro, & Fernando Mendes Sant'Anna. (2024). Será a Ablação por Cateter para Fibrilação Atrial em Pacientes com Insuficiência Cardíaca e Fração de Ejeção Reduzida uma Boa Opção Terapêutica? *Arquivos Brasileiros de Cardiologia, 121*(1). https://doi.org/10.36660/abc.20230820

17. Sohns, C., Fox, H., Marrouche, N. F., Harry J.G.M. Crijns, A. Costard-Jaeckle, Bergau, L., Gerhard Hindricks, Nikolaos Dagres, Sossalla, S., Schramm, R., Fink, T., Mustapha

Revista ARACÊ
ISSN: 2358-2472

El Hamriti, M. Moersdorf, Sciacca, V., Konietschke, F., Rudolph, V., Gummert, J., Jan G.P. Tijssen, & Sommer, P. (2023). Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. *The New England Journal of Medicine.* https://doi.org/10.1056/nejmoa2306037

18. Van, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Harry, Tom, Dwight, J., Luigina Guasti, Hanke, T., Jaarsma, T., Maddalena Lettino, Maja-Lisa Løchen, R. Thomas Lumbers, Maesen, B., Mølgaard, I., Rosano, G. M. C., Sanders, P., Schnabel, R. B., & Suwalski, P. (2024). 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *European Heart Journal, 45*(36). https://doi.org/10.1093/eurheartj/ehae176